Abeona Therapeutics Inc. (0H7R.L)
USD 5.88
(-2.0%)
USD 5.88
(-2.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.5 Million USD | 147.52% |
| 2022 | 1.41 Million USD | -52.87% |
| 2021 | 3 Million USD | -70.0% |
| 2020 | 10 Million USD | 0.0% |
| 2019 | - USD | -100.0% |
| 2018 | 2.99 Million USD | 258.18% |
| 2017 | 837 Thousand USD | -5.85% |
| 2016 | 889 Thousand USD | -14.52% |
| 2015 | 1.04 Million USD | 12.43% |
| 2014 | 925 Thousand USD | -54.7% |
| 2013 | 2.04 Million USD | -53.63% |
| 2012 | 4.4 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | - USD | 0.0% |
| 2024 Q1 | - USD | 0.0% |
| 2023 Q3 | - USD | -100.0% |
| 2023 FY | 3.5 Million USD | 147.52% |
| 2023 Q2 | 3.5 Million USD | 0.0% |
| 2023 Q4 | - USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2022 FY | 1.41 Million USD | -52.87% |
| 2022 Q3 | - USD | -100.0% |
| 2022 Q2 | 1 Million USD | 189.02% |
| 2022 Q1 | 346 Thousand USD | -88.47% |
| 2022 Q4 | 68 Thousand USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q4 | 3 Million USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q1 | - USD | -100.0% |
| 2021 FY | 3 Million USD | -70.0% |
| 2020 Q3 | 7 Million USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 FY | 10 Million USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q4 | 3 Million USD | -57.14% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | - USD | -100.0% |
| 2019 Q1 | - USD | -100.0% |
| 2018 Q1 | 531 Thousand USD | 146.98% |
| 2018 Q3 | 1.7 Million USD | 519.2% |
| 2018 Q4 | 482 Thousand USD | -71.8% |
| 2018 FY | 2.99 Million USD | 258.18% |
| 2018 Q2 | 276 Thousand USD | -48.02% |
| 2017 Q3 | 219 Thousand USD | 0.92% |
| 2017 Q2 | 217 Thousand USD | 16.67% |
| 2017 Q1 | 186 Thousand USD | -27.34% |
| 2017 FY | 837 Thousand USD | -5.85% |
| 2017 Q4 | 215 Thousand USD | -1.83% |
| 2016 Q3 | 184 Thousand USD | -14.02% |
| 2016 FY | 889 Thousand USD | -14.52% |
| 2016 Q4 | 256 Thousand USD | 39.13% |
| 2016 Q2 | 214 Thousand USD | -8.94% |
| 2016 Q1 | 235 Thousand USD | 9.3% |
| 2015 Q4 | 215 Thousand USD | -24.56% |
| 2015 Q2 | 282 Thousand USD | 9.3% |
| 2015 Q1 | 258 Thousand USD | 10.26% |
| 2015 FY | 1.04 Million USD | 12.43% |
| 2015 Q3 | 285 Thousand USD | 1.06% |
| 2014 FY | 925 Thousand USD | -54.7% |
| 2014 Q4 | 234 Thousand USD | -0.85% |
| 2014 Q2 | 247 Thousand USD | 18.75% |
| 2014 Q3 | 236 Thousand USD | -4.45% |
| 2014 Q1 | 208 Thousand USD | 28.4% |
| 2013 FY | 2.04 Million USD | -53.63% |
| 2013 Q1 | 1.22 Million USD | 21.67% |
| 2013 Q2 | 467 Thousand USD | -61.85% |
| 2013 Q3 | 189 Thousand USD | -59.53% |
| 2013 Q4 | 162 Thousand USD | -14.29% |
| 2012 FY | 4.4 Million USD | 0.0% |
| 2012 Q4 | 1 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | 95.52% |
| Dynavax Technologies Corporation | 232.28 Million USD | 98.493% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 99.424% |
| Perrigo Company plc | 4.65 Billion USD | 99.925% |
| Illumina, Inc. | 4.5 Billion USD | 99.922% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.992% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -194.365% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.998% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 99.977% |
| Heron Therapeutics, Inc. | 127.04 Million USD | 97.245% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 99.973% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 2.95 Billion USD | 99.882% |
| Biogen Inc. | 9.83 Billion USD | 99.964% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | 98.014% |
| Evolus, Inc. | 202.08 Million USD | 98.268% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 20.96 Million USD | 83.308% |
| bluebird bio, Inc. | 29.49 Million USD | 88.134% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 96.991% |
| FibroGen, Inc. | 147.75 Million USD | 97.631% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 99.949% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 152.624% |
| Geron Corporation | 237 Thousand USD | -1376.793% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 99.809% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 99.124% |
| Myriad Genetics, Inc. | 678.4 Million USD | 99.484% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | 90.351% |
| Zoetis Inc. | 8.54 Billion USD | 99.959% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 99.908% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 99.855% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 99.965% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 99.556% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | 59.174% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 90.12 Million USD | 96.116% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 98.707% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | 88.8% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 99.718% |
| OPKO Health, Inc. | 863.49 Million USD | 99.595% |
| Exelixis, Inc. | 1.83 Billion USD | 99.809% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.815% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 99.274% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | 77.908% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 249.38 Million USD | 98.597% |
| Insmed Incorporated | 305.2 Million USD | 98.853% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 99.578% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | 86.951% |
| TG Therapeutics, Inc. | 233.66 Million USD | 98.502% |
| Incyte Corporation | 3.69 Billion USD | 99.905% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 99.666% |